December 17, 2009
Another question from the recent Drug Benefit News where I was interviewed with several other experts on the industry. My answer…
- How to continue to grow (top line, bottom line, marketshare, functionality, internationally)?
- How to avoid commoditization within specialty and how to scale specialty operations with a lower FTE to Rx ratio without impacting outcomes?
- How to prevent “churn” from mail whether due to non-adherence or movement to $4 generic type programs?
- How to simplify consumer messaging and drive health outcomes?
- How to develop restrictive benefits that drive behavior with minimal disruption?
- How to structure client and pharma financial relationships that reward them for better outcomes?
Other thoughts?
No comments yet... Be the first to leave a reply!